Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
Introduction: Antipsychotic-induced dyslipidemia represents a common adverse effect faced by patients with schizophrenia that increases risk for developing further metabolic complications and cardiovascular disease. Despite its burden, antipsychotic-induced dyslipidemia is often left untreated, and...
Main Authors: | Pruntha Kanagasundaram, Jiwon Lee, Femin Prasad, Kenya A. Costa-Dookhan, Laurie Hamel, Madeleine Gordon, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.642403/full |
Similar Items
-
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
by: Nicole E. MacKenzie, et al.
Published: (2018-12-01) -
Editorial: Cardiovascular and Physical Health in Severe Mental Illness
by: Sri Mahavir Agarwal, et al.
Published: (2021-09-01) -
Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
by: Kenya A. Costa-Dookhan, et al.
Published: (2021-01-01) -
The Diabetogenic Effects of Antipsychotic Medications: From Rodents to Humans
by: Hahn, Margaret
Published: (2013) -
The Diabetogenic Effects of Antipsychotic Medications: From Rodents to Humans
by: Hahn, Margaret
Published: (2013)